Lena Marshall
159 stories · Page 7 of 7
Calcium and Vitamin D Got Demoted in the BMJ. The Trial Data Are More Stubborn Than the Headline.
A BMJ meta-analysis of 153,902 older adults reports calcium and vitamin D supplements offer little meaningful benefit against fractures and falls, though the combined arm showed a statistically significant 16% reduction in hip fracture risk.
Drugs & FDAA Fentanyl Vaccine for Mice. An Overdose Decline for Humans.
Scripps Research published a clever chemistry redesign that let mice's immune systems recognize an entire class of fentanyl analogues. The headlines called it an overdose blocker. The mice are doing fine. Humans are years away, and the overdose decline is already happening without it.
CancerA Korean lab found cancer's DNA-repair off-switch. In a mouse.
A Korean state lab reports that a tool compound called UNI418 strips out the DNA-repair proteins cancer cells use to escape PARP inhibitors. The data are preclinical: cell lines and mouse xenografts. UNI418 is not yet a drug.
Infectious DiseaseThe AI Vaccine That 'Passed' Its First Trial Three Years Ago
Cambridge finished the Phase 1 trial in 2023. The press tour arrived in 2026. The paper, when you read it, said the immunogenicity was modest.
Drugs & FDAThe Macaques Get a Reprieve. Pharma Gets a Faster Pipeline.
The FDA's new draft guidance lets oncology developers cut animal studies for certain biologics and conjugated products. The replacement laboratory methods are still being validated.
CancerSix melanoma patients, six weeks, one common variable: the question oncology is choosing not to study
An oncologist's bedside pattern, a Senate hearing, and a mechanism paper sitting in a mainstream oncology journal: the case that repeated mRNA boosters may be lifting the brakes off cancers oncologists thought they had quiet is no longer fringe enough to wave away.
CancerALTAIR Missed Its Primary Endpoint. The Press Tour Found Something Else.
A phase 3 trial testing chemotherapy in ctDNA-positive colorectal cancer patients missed its primary endpoint at p=0.107, and a post-hoc reanalysis is doing the public-facing work.
Metabolic & WeightThe Ozempic 'Resistance' Headline the Data Didn't Quite Earn
A new study identifies PAM-gene variants tied to weaker six-month HbA1c response to GLP-1 diabetes drugs, but the 'why Ozempic may not work' framing imports a weight-loss conclusion the paper doesn't reach, and the buried trials that used longer-acting GLP-1 drugs showed no carrier effect at all.
InvestigationsThe $401 CBC and the $32 CBC Are the Same Test
A Reddit pitch for a Quest reseller put receipts on a markup the insurance-billed lab market has spent years obscuring. A Florida cost study confirms what the consumer market already figured out.
CancerOzempic's 30 Percent Breast-Cancer Headline, and the Trial Evidence It Walked Past
A single-system observational study at ASCO 2026 attached a roughly 30% lower breast-cancer rate to GLP-1 use. The randomized record already on the table is quieter.
CancerPancreatic cancer's undruggable wall just cracked. The follow-up is 8.5 months and the money was already placed.
Revolution Medicines' daraxonrasib nearly doubled median overall survival versus chemotherapy in previously treated metastatic pancreatic cancer at ASCO 2026, with 8.5 months of follow-up and a two-billion-dollar Royalty Pharma deal already riding on what comes next.
InvestigationsA Senate hearing finally put the cancer question on the record. The journal notice had been up for months.
Sen. Ron Johnson's June 3 subcommittee hearing on plausible mechanisms linking mRNA injections to cancer, the South Korean cohort behind it, and the editorial notice Springer had posted on the paper months earlier.
Nutrition & FoodYale's Olive Oil Cancer Story Did Not Actually Test Olive Oil
A Yale mouse study reported in Cancer Discovery is being sold as proof that olive oil fuels pancreatic cancer. The lab fed the mice purified oleic acid, the effect only showed up in males, and no one has tested it in a person.
InvestigationsHalf a Billion in Detainee Health Care, and the Federal Watchdog Quietly Closed
A KFF and AP investigation pulled more than 300 sworn allegations of medical neglect from 33,000 ICE habeas petitions, even as the detention ombudsman office quietly closed and the federal detainee care bill passed half a billion dollars.
Drugs & FDAAndrew Huberman's peptide masterclass and the published evidence
Andrew Huberman's June 1 episode on peptides walks through BPC-157 and seven other compounds. The published human evidence for its lead substance runs to fewer than thirty people.